Hepatitis C drug developers see shares rise after news of Roche acquisition Print E-mail
By M.E.Garza   
Tuesday, 18 October 2011 03:12
FDA CalendarOn Monday, there was a rise in share prices for companies who are studying potential new treatments for hepatitis C. This after Swiss drugmaker Roche agreed to buy Anadys Pharmaceuticals (Nasdaq:ANDS) for $230 million.

Industry observers beleive the deal could mean greater competition for the two recently approved hepatitis C drugs, Vertex's (NASDAQ:VRTX) Incivek and Merck and Co.'s (NYSE:MRK) Victrelis. Food and Drug Administration regulators cleared both drugs for marketing in May and a report from the Associated Press indicates that analysts expect both companies to generate billions in sales from both drugs.

Hepatitis C is a viral disease that leads to swelling (inflammation) and damage to the liver. Most people who were recently infected with hepatitis C do not have symptoms and about 4 million Americans have the disease, and many are undiagnosed.

Although the recently approved drugs for the disease marked the first breakthroughs for hepatitis C treatments in approximately 20 years, a number of other companies are researching other treatments and drugs. Researchers at those firms hope that these new drugs have better cure rates and that they can be used for less time, reducing side effects.

Roche's deal values Anadys at $3.70 per share, more than triple its Friday closing price of $1.04. The stock closed at $3.66 on Monday- rising 250% during regular trading session hours after trading 45,839,427 shares- about a 9000% increase above the average.

JMP Securities analyst Liisa Bayko sent a note to clients saying that she expects she expects more hepatitis drug developers to be acquired. "We anticipate more deal making in the hepatitis C virus space in 2012 as companies accrue longer-term safety data on the earlier stage assets in the pipeline," she wrote.

Also rising were shares of Achillion Pharmaceuticals (NASDAQ:ACHN) 5.89+0.07 (1.20%), Idenix Pharmaceuticals Inc.(NASDAQ:IDIX) 5.15+0.01 (0.19%), and a stock we told our readers about last week: Inhibitex Inc. (NASDAQ:INHX) continued to force shorts to cover as it climbed closing at $3.63+0.43 (13.44%).

Inhibitex shares, which have been climbing during the past few sessions, broke past an important point of price resistance at the $3.35 level, and must now make it past $3.67 in order to match their 52-Wk High of $ 5.23.

As we previsouly reported, smart money likes Inhibitex. Institutions own 63.20% of the firm's 78.3M shares. Trading volume had been higher than average by approximately 300% during the past few sessions, but volume shot up nearly 500% on Monday and many of those with short positions in the stock covered their position and added to the buying pressure.

Any number of these biotech firms could become an acquisition target for Big Pharma. Achillion is conducting human trials of three potential hepatitis C drugs and preclinical studies of a fourth. Its most advanced drug candidate, ACH-1625, is in mid-stage trials. Last month, Inhibitex announced that it had commenced dosing in a 90-patient randomized, placebo controlled, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naïve patients. Results are expected in sometime in the first quarter of 2012.

Achillion and Inhibitex do not have any products on the market, while Idenix already gets royalties on sales of the hepatitis C drug Tyzeka and is the largest of the four companies, with a market capitalization of about $500 million..

Prior to the aquisition, Anadys did not have any approved products, but it is studying two potential hepatitis C treatments.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus